Entera Bio Ltd. WT EXP 062723 (ENTXW) Stock Analysis
DELISTED 2023
What happened to Entera Bio Ltd. WT EXP 062723 (ENTXW) stock?
Entera Bio Ltd. WT EXP 062723 (ENTXW) no longer trades on public markets. It was delisted in June 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Entera Bio Ltd. WT EXP 062723 (ENTXW) trades at $0.0012. Entera Bio Ltd. WT EXP 062723 is a pharmaceutical company focused on developing orally delivered large molecule therapeutics. Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for ENTXW: ENTXW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ENTXW against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
ENTXW: 1/2 scored disciplines lean bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →Entera Bio Ltd. WT EXP 062723 (ENTXW) Healthcare & Pipeline Overview
Entera Bio Ltd. WT EXP 062723's warrants (ENTXW) offer exposure to the potential upside of Entera Bio's oral drug delivery technology. These warrants, expiring in June 2023, are linked to the company's efforts in developing oral formulations of large molecule therapeutics, primarily targeting osteoporosis and related bone diseases. The warrants' value is tied to Entera Bio's clinical and commercial success.
What Is the Investment Thesis for ENTXW?
Investing in Entera Bio Ltd. WT EXP 062723 (ENTXW) is a speculative bet on the future success of Entera Bio's oral drug delivery technology. The value of these warrants, which expired in June 2023, was contingent on Entera Bio achieving key clinical and regulatory milestones. The potential upside was linked to the successful development and commercialization of its oral biologics pipeline, particularly its lead product candidate for osteoporosis. However, the warrants' expiration means they no longer hold value. Investors may want to evaluate the high-risk, high-reward nature of biotechnology investments and the specific risks associated with warrant investments.
Based on FMP financials and quantitative analysis
ENTXW Key Highlights
P/E ratio of -5.55 indicates the company is currently not profitable.
- Profit Margin of -8694.4% reflects significant losses relative to revenue.
- Gross Margin of -6.5% suggests the cost of goods sold exceeds revenue.
- The company does not offer a dividend, indicating a focus on reinvesting earnings for growth.
- Entera Bio's focus on oral delivery of large molecule therapeutics differentiates it from traditional injectable therapies.
Who Are ENTXW's Competitors?
ENTXW is benchmarked below against 5 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ESALY Eisai Co., Ltd. | $61.51 | -2.11% | $17.6B | 57 |
| FPHAX Fidelity Select Pharmaceuticals | $35.95 | -3.00% | $1.29B | 47 |
| ELAT Elanco Animal Health Inc | $21.32 | +1.04% | 50 | |
| AMRT American Mart Corporation | $110.00 | +0.00% | 46 | |
| CORI Corium International, Inc. | $12.68 | +0.00% | 44 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ENTXW's Key Strengths?
Proprietary oral drug delivery technology.
- Focus on large molecule therapeutics.
- Potential to replace injectable therapies.
- Addressing unmet needs in bone and metabolic disorders.
What Are ENTXW's Weaknesses?
Negative profit margin and gross margin.
- Dependence on successful clinical trials.
- High research and development costs.
- Limited commercialized products.
What Could Drive ENTXW Stock Higher?
Clinical trial results for lead product candidate.
- Development of new oral formulations.
- Strategic partnerships and collaborations.
What Are the Key Risks for ENTXW?
Unsuccessful clinical trial results.
- Regulatory approval delays.
- Competition from established pharmaceutical companies.
- High research and development costs.
- Negative profit margin and gross margin.
What Are the Growth Opportunities for ENTXW?
- Expansion into new therapeutic areas: Entera Bio can leverage its oral drug delivery platform to develop oral formulations of biologics for other indications beyond osteoporosis, such as diabetes, obesity, and inflammatory diseases. The market for oral biologics is estimated to reach $XX billion by 2030, presenting a significant growth opportunity for Entera Bio. Timeline: Ongoing.
- Strategic partnerships with pharmaceutical companies: Entera Bio can collaborate with established pharmaceutical companies to co-develop and commercialize its oral biologics. These partnerships can provide Entera Bio with access to funding, expertise, and distribution channels, accelerating the development and commercialization of its products. Timeline: Ongoing.
- Successful clinical trials and regulatory approvals: The successful completion of clinical trials and the receipt of regulatory approvals for its lead product candidate for osteoporosis will be a major growth driver for Entera Bio. Positive clinical data will validate its technology platform and increase investor confidence. Timeline: Dependent on clinical trial outcomes.
- Geographic expansion: Entera Bio can expand its geographic reach by commercializing its products in new markets, such as Europe and Asia. These markets represent significant growth opportunities, given the large patient populations and the increasing demand for innovative therapies. Timeline: 3-5 years.
- Development of next-generation oral biologics: Entera Bio can invest in research and development to develop next-generation oral biologics with improved efficacy, safety, and bioavailability. These advancements can further differentiate Entera Bio from its competitors and strengthen its market position. Timeline: 5+ years.
What Threats Does ENTXW Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles and approval delays.
- Patent challenges and intellectual property disputes.
- Unsuccessful clinical trials.
What Are ENTXW's Competitive Advantages?
- Proprietary oral drug delivery technology platform.
- Patent protection for its formulations and methods.
- Clinical data demonstrating efficacy and safety.
- First-mover advantage in the oral biologics market.
What Does ENTXW Do?
Entera Bio Ltd. is a biopharmaceutical company focused on the development and commercialization of orally delivered formulations of large molecule therapeutics. Founded with the goal of transforming the delivery of biologics, Entera Bio leverages its proprietary technology platform to enable the oral administration of drugs that are typically delivered via injection. The company's primary focus is on addressing unmet needs in bone and metabolic disorders, with a lead product candidate targeting osteoporosis. Entera Bio's technology aims to improve patient compliance, convenience, and overall treatment outcomes by replacing injectable therapies with oral alternatives. The company's research and development efforts are centered on advancing its pipeline of oral biologics, with the goal of providing innovative solutions for patients with chronic diseases. Entera Bio's warrants, ENTXW, represent the right to purchase shares of the company's common stock, offering investors a leveraged opportunity to participate in the company's potential success. However, these warrants expired in June 2023.
What Products and Services Does ENTXW Offer?
- Develops oral formulations of large molecule therapeutics.
- Focuses on addressing unmet needs in bone and metabolic disorders.
- Utilizes a proprietary technology platform to enable oral delivery of biologics.
- Aims to replace injectable therapies with oral alternatives.
- Conducts research and development to advance its pipeline of oral biologics.
- Targets osteoporosis with its lead product candidate.
How Does ENTXW Make Money?
- Develops and patents oral drug delivery technology.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from health authorities.
- May partner with pharmaceutical companies for commercialization.
- Generates revenue through product sales and licensing agreements.
What Industry Does ENTXW Operate In?
Entera Bio operates within the competitive pharmaceutical industry, specifically targeting the oral delivery of large molecule therapeutics. The market for oral biologics is driven by the desire for more convenient and patient-friendly drug delivery methods. The osteoporosis market, in particular, represents a significant opportunity for Entera Bio, given the large patient population and the limitations of existing injectable therapies. Competitors are working on alternative delivery methods and novel treatments for bone and metabolic disorders. The industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition.
Who Are ENTXW's Key Customers?
- Patients with osteoporosis and other bone disorders.
- Physicians who prescribe treatments for these conditions.
- Pharmacies that dispense medications.
- Hospitals and clinics that administer therapies.
Company Profile
Entera Bio Ltd. WT EXP 062723 operates in the Biotechnology industry within the Healthcare sector. ENTXW has traded publicly since 2018.
Key Financial Metrics
Return on equity for Entera Bio Ltd. WT EXP 062723 stands at 70.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 42.0%, showing how much profit it generates from its asset base. ENTXW trades at a trailing price-to-earnings ratio of 0.01, below the Healthcare sector average of ~23x. A current ratio of 8.98 indicates the company holds enough short-term assets to cover its near-term obligations.
ENTXW Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying could signal confidence in Entera Bio's future prospects, suggesting they believe the company is undervalued.
- The community seems optimistic about Entera Bio's oral peptide delivery technology, viewing it as a potential game-changer in the treatment of osteoporosis.
- Positive community sentiment suggests a belief in the efficacy of Entera Bio's pipeline and its potential to address unmet medical needs.
- Market perception indicates a growing interest in alternative drug delivery methods, which could benefit Entera Bio's unique approach.
Bear Case
- The expiration of the warrants could create selling pressure as holders look to cash out, potentially impacting the stock price negatively.
- Community concerns about Entera Bio's cash runway and potential need for further financing could be weighing on sentiment.
- Bearish community views suggest skepticism about the commercial viability of Entera Bio's products and their ability to compete with existing treatments.
- Market perception indicates uncertainty surrounding the regulatory pathway for Entera Bio's oral peptide therapies, potentially delaying approval.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ENTXW Latest News
No recent news available for ENTXW.
Leadership: None
CEO title
Due to the absence of CEO information, this section remains incomplete. Typically, this section would detail the CEO's professional history, including previous roles, education, and any relevant experience in the pharmaceutical or biotechnology industries. This background helps investors assess the CEO's suitability for leading the company and executing its strategic vision.
Track Record: Due to the absence of CEO information, this section remains incomplete. A typical track record would highlight key achievements, strategic decisions, and company milestones achieved under the CEO's leadership. This provides investors with insights into the CEO's ability to drive growth and create value for shareholders.
ENTXW Healthcare Stock FAQ
What happened to Entera Bio Ltd. WT EXP 062723 (ENTXW) stock?
Entera Bio Ltd. WT EXP 062723 (ENTXW) no longer trades on public markets. It was delisted in June 2023. The figures below are historical and are not a current quote.
Can I still buy ENTXW shares?
No. ENTXW stopped trading on public markets in June 2023, so the shares are not available through a broker. Anything you see quoted for ENTXW elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before ENTXW stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Entera Bio Ltd. WT EXP 062723. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Entera Bio Ltd. WT EXP 062723 do?
Entera Bio Ltd. is a biopharmaceutical company focused on developing and commercializing orally delivered formulations of large molecule therapeutics. Their proprietary technology aims to transform the delivery of biologics, typically administered via injection, into oral alternatives. The company's primary focus is on bone and metabolic disorders, with a lead product candidate targeting osteoporosis.
What are the main risks for ENTXW?
The main risks for Entera Bio Ltd. include the inherent uncertainties of pharmaceutical development, such as unsuccessful clinical trial results and regulatory approval delays. Competition from established pharmaceutical companies and alternative treatments also poses a significant risk. Financial risks include high research and development costs and the need to raise additional capital. The warrants (ENTXW) expired in June 2023, rendering them valueless.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending.
- Information based on available financial data and company description.
- The warrants (ENTXW) expired in June 2023.